SPY336.83-0.61 -0.18%
DIA279.42-0.62 -0.22%
IXIC11,042.50+30.27 0.27%

Galmed Pharmaceuticals Q3 EPS $(0.21) Beats $(0.29) Estimate

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.29) by 27.59 percent. This is a 320 percent decrease over losses of $(0.05) per share

Benzinga · -

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.29) by 27.59 percent. This is a 320 percent decrease over losses of $(0.05) per share from the same period last year.